// App-Quantinova.ai

440 : Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.

Researchers

Presenter

  • Syed A. Hussain

Principal Investigators

  • Nobuaki Shimizu

  • Wataru Obara

  • Toshinari Yamasaki

  • Satoru Takashima

  • Takahiro Hasegawa

  • Motofumi Iguchi

  • Kenji Igarashi

  • Osamu Ogawa

  • Tomoaki Fujioka

Medical Centers

  • Department of Oncology & Metabolism, University of Sheffield, Sheffield, United Kingdom

  • Department of Breast Oncology, Gunma Prefectural Cancer Center, Gunma, Japan

  • Department of Neurosurgery, Iwate Medical University, Morioka, Japan

  • Department of Radiology, Okayama University Graduate School of Medicine, Okayama, Japan

  • Clinical Development Department, Shionogi & Co., Ltd., Osaka, Japan

  • Biostatistics, Shionogi & Co., Ltd., Osaka, Japan

  • Medical Science, Shionogi & Co., Ltd., Osaka, Japan

  • Project Management, Shionogi & Co., Ltd., Osaka, Japan

Locations

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Major Histocompatibility Complex, Class I, A

Drug/Treatment

  • S588410

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved